Guanfacine extended-release use in diagnostic diversity and symptom complexity
Frontiers in Child and Adolescent Psychiatry · 21.08.2026 · 5
DOI: 10.3389/frcha.2026.1912093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Child and Adolescent Psychiatry, online erschienen am 21.08.2026. Verfasst von Gülenay Korkmaz Şahin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child and Adolescent Psychiatry, Ege University Faculty of Medicine, İzmir, Türkiye. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This retrospective chart review examined clinical changes in ADHD symptoms and global functioning following guanfacine extended-release (GXR) initiation in a diagnostically heterogeneous clinical sample of children and adolescents with ADHD.
Methods
Thirty-eight children and adolescents aged 6–18 years with ADHD, with or without comorbid neurodevelopmental or psychiatric conditions, who were prescribed guanfacine extended-release were included in the tolerability analysis. Pre–post clinical outcome analyses were conducted in 33 patients who continued GXR for at least three months and had follow-up scale assessments available between weeks 4 and 12 after treatment initiation. Clinical data, including ADHD-related rating scales and autism-related clinical measures, were obtained retrospectively from medical records. Diagnoses were based on DSM-5 criteria, and psychiatric comorbidities were assessed using K-SADS-PL.
Results
Of the participants, 76.3% were male. All participants had ADHD, and 63.2% had comorbid ASD. The mean final weight-adjusted GXR dose was 0.05 ± 0.03 mg/kg/day. Adverse effects were reported in 28.9% of patients, most commonly restlessness. Among 33 patients with follow-up assessments obtained between weeks 4 and 12, median CGI-S scores decreased from 5 to 3, while GAS scores increased from 55 to 75. ADHD symptom ratings decreased in most Turgay scale subdomains, particularly attention deficit, hyperactivity/impulsivity, and oppositional defiant symptoms.
Conclusion
Guanfacine extended-release use was associated with improvements in ADHD symptom ratings and global functioning in this retrospective clinical sample. Adverse effects were observed in a clinically relevant subset of patients and led to discontinuation in some cases. Given the retrospective design, lack of a control group, small sample size, and concomitant medication use, these findings should be interpreted as preliminary real-world observations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Child and Adolescent Psychiatry, Ege University Faculty of Medicine, İzmir, Türkiye.
- Department of Child and Adolescent Psychiatry, Behçet Uz Training and Research Hospital, İzmir, Türkiye.
Zitieren
APA
Şahin, G. K., Sarı, S., Şener, Z. İ., & Özbaran, N. B. (2026). Guanfacine extended-release use in diagnostic diversity and symptom complexity. Frontiers in Child and Adolescent Psychiatry, 5. https://doi.org/10.3389/frcha.2026.1912093
Vancouver
Şahin GK, Sarı S, Şener Zİ, Özbaran NB. Guanfacine extended-release use in diagnostic diversity and symptom complexity. Frontiers in Child and Adolescent Psychiatry. 2026;5. doi:10.3389/frcha.2026.1912093
BibTeX
@article{ahin2026,
author = {Şahin, Gülenay Korkmaz and Sarı, Seda and Şener, Zeynep İrem and Özbaran, Nazlı Burcu},
title = {Guanfacine extended-release use in diagnostic diversity and symptom complexity},
journal = {Frontiers in Child and Adolescent Psychiatry},
year = {2026},
volume = {5},
doi = {10.3389/frcha.2026.1912093}
}
EUVIMED